Clinical trials: Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption. Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide…
- Trial name
- ExCentric (NCT01124240)
- Testing
- Cilengitide
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Northern Sydney and Central Coast Area Health Service